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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an incurable and debilitating chronic disease
characterized by progressive airflow limitation associated with abnormal levels of tissue inflammation. Therefore,
stem cell-based approaches to tackle the condition are currently a focus of regenerative therapies for COPD.
Extracellular vesicles (EVs) released by all cell types are crucially involved in paracrine, extracellular communication.
Recent advances in the field suggest that stem cell-derived EVs possess a therapeutic potential which is comparable to
the cells of their origin.
Methods: In this study, we assessed the potential anti-inflammatory effects of human umbilical cord mesenchymal
stem cell (hUC-MSC)-derived EVs in a rat model of COPD. EVs were isolated from hUC-MSCs and characterized by the
transmission electron microscope, western blotting, and nanoparticle tracking analysis. As a model of COPD, male
Sprague-Dawley rats were exposed to cigarette smoke for up to 12 weeks, followed by transplantation of hUC-MSCs or
application of hUC-MSC-derived EVs. Lung tissue was subjected to histological analysis using haematoxylin and eosin
staining, Alcian blue-periodic acid-Schiff (AB-PAS) staining, and immunofluorescence staining. Gene expression in the
lung tissue was assessed using microarray analysis. Statistical analyses were performed using GraphPad Prism 7 version
7.0 (GraphPad Software, USA). Student’s t test was used to compare between 2 groups. Comparison among more than
2 groups was done using one-way analysis of variance (ANOVA). Data presented as median ± standard deviation (SD).
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Results: Both transplantation of hUC-MSCs and application of EVs resulted in a reduction of peribronchial and
perivascular inflammation, alveolar septal thickening associated with mononuclear inflammation, and a decreased
number of goblet cells. Moreover, hUC-MSCs and EVs ameliorated the loss of alveolar septa in the emphysematous
lung of COPD rats and reduced the levels of NF-κB subunit p65 in the tissue. Subsequent microarray analysis revealed
that both hUC-MSCs and EVs significantly regulate multiple pathways known to be associated with COPD.
Conclusions: In conclusion, we show that hUC-MSC-derived EVs effectively ameliorate by COPD-induced inflammation.
Thus, EVs could serve as a new cell-free-based therapy for the treatment of COPD.
Keywords: COPD, Umbilical cord mesenchymal stem cells, Extracellular vesicles, An animal model
Introduction
The pathogenesis of the chronic obstructive pulmonary
disease (COPD) is characterized by chronic inflamma-
tion that leads to small airway obstruction and emphy-
sema [54]. Systemic analysis for Global Burden of Study
2010 demonstrated COPD to be the third leading cause
of death in 2010 [57]. Eighty to 90% of all COPD cases
are caused by exposure to cigarette smoke (CS) [14]. In-
halation of CS increases the number of neutrophils, B
cells, macrophages, and CD8+ T cells in the small airway
and lungs. These cells, in turn, release multiple inflam-
matory cytokines, proteinases, and chemokines that
together contribute to the degeneration of lung paren-
chyma [17, 72]. Symptoms of COPD include chronic
cough, dyspnea, and excessive production of sputum
while anorexia, fatigue, and weight loss may present in
patients with severe COPD [13].
Mesenchymal stem cells (MSCs) are multipotent stem
cells capable of differentiating into osteoblasts, adipo-
cytes, and chondroblast lineages [16, 29]. Apart from the
bone marrow (BM), MSCs can be isolated from various
tissue including the umbilical cord (UC), placenta, adi-
pose tissue (AT), amniotic fluid, and lung tissue [56].
However, UC represents an attractive source of MSCs as
UC-MSCs are a less ethical concern like embryonic stem
cells, and the isolation of UC-MSCs is non-invasive as
compared to BM-MSCs. Besides, UC-MSCs have been
shown to have similar efficacy in modulating the inflam-
mation as BM-MSCs [46]. In another study, UC-MSCs
depicted a greater proliferation, slower senescence rate,
and greater anti-inflammatory effect as compared to
BM-MSCs and AT-MSCs, suggesting that UC-MSCs
might be a better alternative for stem cell-based therapy
[44]. Multiple pre-clinical studies suggest that MSCs
have the potential to ameliorate the symptoms of many
lung diseases such as pulmonary hypertension, asthma,
COPD, and pulmonary fibrosis [23, 35, 52, 93]. In the
animal model of smoke-induced pulmonary emphysema,
biweekly administration of adipose-derived MSCs de-
creases the level of inflammation, apoptosis, and alveolar
enlargement [70]. The result from the first phase of clin-
ical trials also demonstrates multiple doses of MSCs to
be safe when administered in COPD patients while redu-
cing the C-reactive protein at 1 month after transplant-
ation [83]. A study in elastase-induced emphysema
demonstrated that two doses of MSCs are better than
single-dose MSCs. These effects are by decreasing the
TNF-α, neutrophil, and lymphocyte count in bronchoal-
veolar lavage fluid; the thymus weight; and the severity
of hypertension and increased elastic fibre content in the
lung [66]. However, a recent study had demonstrated
the efficacy of a single dose of UC-MSC in moderate-to-
severe COPD patients, where the study was reported the
UC-MSC was well tolerated with no clinically significant
adverse effects reported, decreased number of exacerba-
tions in COPD Assessment Test (CAT) and mMRC
scores, and the patients shown a significantly improved
in terms of the quality of life [8].
Recently, an increasing number of researches have fo-
cused on studying the therapeutic effects of EVs in vari-
ous diseases. EVs are small membrane vesicle of
multivesicular bodies heterogeneous in size released by a
variety of cell types, including MSCs. Extracellular vesi-
cles can be found in body fluids such as milk, saliva,
urine, amniotic fluid, and cerebrospinal fluid. There are
two commonly studied EVs which are exosomes and
microvesicles. Exosomes, the size ranges from 40 to 100
nm, are originated from the inward budding of endo-
some that forms multivesicular bodies (MVB) and re-
leased when the MVB fused with the cell membrane
[69], while microvesicles (MV), also known as shed
microvesicles with a size ranging from 50 to 1000 nm,
are formed by outward budding of the cell membrane
[68]. The isolation of EVs can be conducted via various
methods, including differential ultracentrifugation, dens-
ity gradient separation, and immunoaffinity capture [34].
The cargo of EVs is proteins, lipids, messenger ribo-
nucleic acid (mRNA), and microRNA (miRNA) which
act as messenger molecules in intercellular communica-
tion [58, 91].
Studies have shown that EVs isolated from MSCs
mimic the therapeutic effects of MSCs and participate in
immunomodulation and regeneration in many animal
models; however, MSCs depicted better effect in
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ameliorating the lung injury as compared to its secreted
factors [38, 76]. MSC-EVs have been reported to reduce
the infarct size in mouse model of myocardial ischemia/
reperfusion injury [50]. MSC-EVs were also capable of
alleviating inflammation, oxidative stress, and apoptosis
[88]. Besides, the use of EVs has been recently suggested
as a potential treatment option for COPD [45, 63]. How-
ever, to our knowledge, no attempts have yet been made
to compare the impact of MSC transplantation to EV ad-
ministration for in vivo models of COPD. In this study, we
examined the effect of human umbilical cord MSCs
(hUC-MSCs) and hUC-MSC-derived EVs on inflamma-
tion, airway remodelling, and emphysema in a rat model
of COPD. In this study, we opted to use cigarette smoke
to induce the inflammation in COPD 2 times/day, 7 days/
week for 12 weeks, following the method from Zheng
et al. [95] with slight modification. Twelve weeks of
cigarette smoke exposure was chosen as our model as in-
flammation, increased goblet cell count, and emphysema
were readily observed in this 12-week model [95].
Materials and methods
Preparation of FBS-EV-deprived medium
DMEM/F12 (Thermo Fisher Scientific, USA) supple-
mented with 10% FBS (Thermo Fisher Scientific, USA)
were subjected to ultracentrifugation at 100,000×g at 18
h at 4 °C by using the Type 50.2Ti fixed-angle rotor, Op-
tima L-100K Ultracentrifuge (Beckman Coulter, USA).
The medium was collected and supplemented with 1%
antibiotic antimycotic containing penicillin, strepto-
mycin, and amphotericin B (Thermo Fisher Scientific,
USA) and 1% L-glutamine (Thermo Fisher Scientific,
USA).
Cell culture, generation of conditioned media (CM), and
isolation of EVs
Human umbilical cord-derived MSC (hUC-MSC) pas-
sage 4 was kindly provided by Cryocord Sdn Bhd
(https://cryocord.com.my/). Cell preparation was con-
ducted in the Current Good Manufacturing Practice
(cGMP)-accredited laboratory. The umbilical cord was
shredded and enzymatically digested using collagenase
(Worthington Biochem, USA) for approximately 2 h at
37 °C. The mesenchymal cells were isolated from human
umbilical cord Wharton’s jelly tissue by passing the
tissue through a syringe and needle. hUC-MSCs were
cultured in Dulbecco’s modified Eagle’s medium
(DMEM)—low glucose (Gibco, USA) supplemented
with 10% human serum (Cryocord Sdn Bhd), 100 U/
ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml
amphotericin (Gibco, USA). The hUC-MSCs were
cryopreserved using standard cryopreservation protocol
until being used in the following research experiment.
hUC-MSCs were characterized using flow cytometric
analysis and multilineage differentiation capacity, accord-
ing to the International Society for Cellular Therapy
(ISCT) criteria for MSCs [85]. Positive cell surface
markers CD90, CD105, CD73, CD166, and HLA-ABC
and negative for haematopoietic markers of CD34, CD45,
and HLA-DR were characterized using flow cytometry
analysis. Meanwhile, multilineage differentiation adipo-
genesis, osteogenesis, and chondrogenesis were conducted
using commercially available differentiation kit.
hUC-MSC-CM were obtained from hUC-MSC passage
5 to passage 7. The hUC-MSCs were cultured from a
density of 4000 cells/cm2 in complete medium, made up
of DMEM/F12 (Thermo Fisher Scientific, USA) supple-
mented with 10% FBS (Thermo Fisher Scientific, USA);
1% antibiotic antimycotic containing penicillin, strepto-
mycin, and amphotericin B (Thermo Fisher Scientific,
USA); 1% L-glutamine (Thermo Fisher Scientific, USA);
and 20 ng/ml basic fibroblast growth factor (bFGF)
(Thermo Fisher Scientific, USA) and incubated at 37 °C,
in humidified air with 5% CO2. After 48 h of culture, the
media were changed to FBS-EV-deprived complete
medium for the generation of hUC-MSC conditioned
media (hUC-MSC-CM). After 72 h, hUC-MSC-CM was
collected and concentrated using Amicon® Ultra-15 Cen-
trifugal Filter Devices (Merck Millipore, USA).
For the generation and isolation of hUC-MSC-EVs,
hUC-MSCs were similarly cultured as described above.
After 48 h, the media were changed to FBS-EV-deprived
complete medium. After 72 h, hUC-MSC-CM was col-
lected and subjected to differential centrifugation. First,
centrifugation of hUC-MSC-CM was conducted by
using Kubota 2420 Compact Tabletop Centrifuge
(Kubota, Japan) at 300×g for 10 min to remove the dead
cells. The supernatant was collected and centrifuged
again by using Allegra X-15R Centrifuge Ultracentrifuge
(Beckman Coulter, USA) at 10,000×g for 30 min to re-
move the debris, followed by ultracentrifugation at 100,
000×g for 2 h to precipitate the hUC-MSC-EVs by using
the Type 50.2Ti fixed-angle rotor, Optima L-100K Ultra-
centrifuge (Beckman Coulter, USA). The supernatant
was discarded, and the hUC-MSC-EV pellet was washed
by resuspending in 1xPBS then re-pelleted by ultracen-
trifugation for 1 h. The hUC-MSC-EV pellet was col-
lected and resuspended in 150 μl 1xPBS and used fresh
for the treatments.
Transmission electron microscope
Freshly isolated hUC-MSC-EVs in 150 μl of 1xPBS sus-
pension were loaded onto carbon-coated copper grids
(Ted Pella, USA) and incubated for 10 min. The grid was
blotted with filter paper and stained with 2% uranyl acet-
ate (Ted Pella, USA) for 1 min. Excessive uranyl acetate
was removed, and the grid was let dry for 15 min before
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viewing using Energy Filter TEM Libra-120 (Carl Zeiss
AG, Germany).
Nanoparticle tracking analysis
The particle size of hUC-MSC-EVs was characterized by
nanoparticle tracking analysis (NTA) using a NanoSight
NS300 (Malvern analytical, UK) blue laser system. hUC-
MSC-EVs were diluted with 1xPBS between 1:10 and 1:
20 and loaded into the laser module sample chamber.
The system focuses the laser beam allowing observing
and measuring small particles. Five readings were re-
corded for each hUC-MSC-EV sample.
Western blot
β-Actin and CD63 expression were confirmed with western
blot analysis; 2mg/ml of hUC-MSC-EVs was separated by
using 12% SDS-polyacrylamide gel electrophoresis (PAGE)
and then transferred onto the polyvinylidene difluoride
(PVDF) membrane (Bio-Rad). The membrane was blocked
with 2% BSA for 1 h at room temperature and incubated
with primary antibodies, rabbit monoclonal antibody CD63
(Abcam, Cat. No. ab134045) 1:2000 dilution, and rabbit
monoclonal antibody β-actin (Cell Signaling Technologies,
Cat. No. 4970S) 1:5000 dilution overnight at 4 °C. The
membrane was then washed with PBST and incubated with
fluorescence secondary antibody goat polyclonal anti-rabbit
IgG (Thermo Fisher Scientific, Cat. No. A16097) 1:10,000
dilution for 1 h at room temperature. The secondary anti-
bodies were washed with PBST and developed using a
fluorescence detection system (Licor).
Animal model of COPD
Male Sprague-Dawley (SD) rats (250–350 g) aged 8–9
weeks (n = 36) were obtained from the Animal Research
and Service Centre (ARASC), Universiti Sains Malaysia.
All animal procedures were approved and performed ac-
cording to the ethical standards of the Animal Ethics
Committee of the Universiti Sains Malaysia [No. USM/
Animal Ethics Approval/2016/(104)(812)]. The approved
protocols for the animal study were based on the Guide-
lines for the Care and Use of Animals for Scientific Pur-
poses (USM [43]) which was developed based on the
Malaysian Animal Welfare Act (2015) and guidelines by
the Australian Codes for the Care and Use of Animals
for Scientific Purposes (8th Edition, 2013) and the
Singapore Guidelines on the Care and Use of Animals
for Scientific Purposes.
The in vivo study was conducted in a Good Laboratory
Practice (GLP)-accredited laboratory in Animal Research
Facilities, Advanced Medical and Dental Institute (IPPT),
Universiti Sains Malaysia. The experimental procedure
was conducted as previously described by Zheng et al.
[95] with slight modifications. COPD symptoms and in-
flammation were established by using commercially
available cigarettes, Marlboro (Philip Morris, USA) (each
containing 10.0 mg of tar and 1.0 mg of nicotine). In
total, 36 rats were divided into 6 groups (n = 6): naive
(untreated group), CS (injury group), CSSH (2-week
self-healing group), hUC-MSC-EVs (hUC-MSC-EVs-
treated group), hUC-MSCs (hUC-MSC-treated group),
and hUC-MSC-CM (hUC-MSC-conditioned media-
treated group). All groups except naive were exposed to
sidestream cigarette smoke for 15 min per session, 6 cig-
arettes for 2 sessions, 7 days a week, for 12 weeks in a
smoking chamber (Fig. 1). Rats were left to rest for 2 h
between each session.
Treatments were given via intratracheal delivery in
150-μl vehicle (1xPBS) on day 85 post-cigarette induc-
tion. Rats were anaesthetized intravenously by using
ketamine (50 mg/kg) and xylazine (5 mg/kg). hUC-MSCs
(2.5 × 106), hUC-MSC-EVs isolated from 2.5 × 106 hUC-
MSCs, and hUC-MSC-CM concentrated from 2.5 × 106
hUC-MSCs were used in the experiment. The naive and
CS groups were euthanized on day 85; meanwhile, the
rest of the groups were euthanized on day 99. Rats were
euthanized by using intravenous injection of pentobar-
bital (200 mg/ml) (Dolethal, Lure Cedex, France).
Peripheral blood collection
Peripheral blood (300 μl) was collected from the rat tail
vein and placed into a 1-ml EDTA tube (Greiner Bio-
One, Austria) and subjected to whole blood count using
the Cell Dyn Hematology Analyzer (Abbott, USA).
Histological assessment
Haematoxylin and eosin (H&E) staining was performed
for the analysis and scoring of peribronchial and perivas-
cular inflammation, alveolar inflammation, and emphy-
sema. Meanwhile, Alcian blue-periodic acid-Schiff (AB-
PAS) staining was performed for the analysis of goblet
cell count. Scoring of inflammation within the airway
was conducted using a semi-quantitative analysis. Slides
were blindly coded before a pathologist scored the tis-
sues. The inflammation scoring was performed using the
scale of 0 to 3 based on the presence and intensity of in-
flammatory cell infiltration in the peribronchial and
perivascular areas. Two slides were analysed per animal,
with a total of 5 animals per group. The score was done
according to the following parameters: 0, no inflamma-
tion detected; 1, occasional cuffing with inflammatory
cells; 2, most bronchi and vessels are surrounded by a
thin layer of inflammatory cells (1–5 cells thick); and 3,
most bronchi and vessels are surrounded by a thick layer
of inflammatory cells (> 5 cells thick). Alveolar inflam-
mation scoring was done by grid on tissue section pho-
tos captured by fluorescence microscopy (Olympus,
Japan). One hundred points were counted on random
areas on the slides. Ten areas were analysed on 2 slides
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per animal with a total of 5 animals per group. Goblet
cells were counted using light microscopy (Olympus,
Japan). Five hundred cells were counted, and the num-
ber of goblet cells was divided by the total cells to get a
percentage of goblet cells. One slide per animal with a
total of 5 animals per group was assessed. Emphysema
was evaluated by using the mean linear intercept (Lm),
which measures the enlargement of the alveolar space.
Measurement was done by using × 40 objective and × 10
eyepiece, and photos of the sections were taken and
superimposed with 30 × 30-μm grid. Ten pictures of 2
slides per animal with a total of 5 animals per group
were captured. The number of alveolar intercepts along
the gridline was counted and calculated based on the





N = number of lines across the photographed area
L = length of the line across the photographed area
m = number of intercepts
RNA extraction and microarray analysis
RNA extraction was performed on 30mg of rat lung
from the naive, CS, hUC-MSCs, and hUC-MSC-EVs
groups using the RNeasy Mini Kit (Qiagen, Germany)
following the manufacturer’s instructions. The purity
and concentration of RNA were measured by NanoDrop
ND1000 (Thermo Fisher Scientific, US). RNA integrity
was determined by Agilent RNA 6000 Nanokit (Agilent
Technology, US). cDNA was synthesized and hybridized
at 65 °C for 17 h and viewed using the Agilent SureScan
Microarray Scanner (Agilent Technology, USA). Com-
parison between different sample datasets was normal-
ized and analysed using the Gene Spring software. The
sample datasets were subjected to t test to identify sig-
nificant changes (p < 0.05) between the sample and con-
trol groups. Genes with p < 0.05 and fold change > 2.0
were filtered as significantly regulated. Volcano plot,
heat map, principal component analysis, Venn diagram,
and pathway analysis were generated using the Gene
Spring software. Gene Ontology analysis using Panther
(www.pantherdb.org) was used to classify differentially
expressed genes (DEG) by its functional role. GO terms
with p < 0.05 was considered significantly enriched by
DEG.
Immunofluorescent staining
Immunofluorescent staining was performed to study the
expression of NF-κB subunit p65. Briefly, tissue sections
were deparaffinized in xylene and rehydrated in graded
ethanols. The tissues were blocked with 5% goat serum
for 30min and incubated with primary antibody mouse
monoclonal NF-κB-P65 (F-6) (Santa Cruz Biotechnol-
ogy, USA) 1:200 for 1.5 h in room temperature. After
washing with PBS, slides were incubated with secondary
antibody Alexa Fluor 555 goat anti-mouse IgG (H+L)
(Thermo Fisher Scientific, USA) and counterstained with
DAPI 1:2000 in 1xPBS, and viewed under the IX71
Fluorescence Microscope (Olympus, Japan).
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 7 version 7.0 (GraphPad Software, USA). Com-
parison among more than 2 groups was done using one-
way analysis of variance (ANOVA) with Tukey’s multiple
Fig. 1 The smoking chamber. For each cigarette smoke exposure session, 3 cigarettes were burnt in the compartment (B) and the smoke
produced was continuously ventilated by 2 air pumps (A) to another compartment where the rats were placed (C). Each session lasted for 15
min, and the smoke was simultaneously ventilated out from the chamber into the air through a polyvinyl chloride tube (D)
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comparison test. Data presented as mean ± standard de-
viation (SD). Differences are considered to be statistically
significant when p ≤ 0.05, whereas p ≤ 0.001 was consid-
ered to be highly significant.
Results
Characterization of hUC-MSCs
Mesenchymal stem cells that were isolated from the hu-
man umbilical cord blood were subjected to flowcytome-
try and differentiation analysis. hUC-MSCs were positive
for CD73, CD90, CD105, and CD166 and negative for
CD34, CD45, CD31, and HLA DR DP DQ (Table 1).
Differentiation analysis showed the ability of MSCs to
differentiate into adipocyte evidenced by lipid droplet
formation, osteocyte evidenced by calcification forma-
tion, and chondrocyte evidenced by cell-matrix forma-
tion (Fig. 2).
Characterization of hUC-MSC-EVs
hUC-MSC-EVs were isolated by differential centrifuga-
tion to remove cell debris and apoptotic bodies. hUC-
MSC-EVs pellet suspended in 1xPBS was characterized
based on morphology, size distribution, and protein
marker expression. Energy-filtered transmission electron
microscopy examination showed hUC-MSC-EVs were
rounded in shape with an average size of 200 nm
(Fig. 3a). Western blot analysis revealed the presence of
the specific exosome marker CD63 at 30–65 kDa and β-
actin at 42 kDa (Fig. 3b). Nanoparticle tracking analysis
of hUC-MSC-EVs showed an average diameter of 153
nm (Fig. 3c). Table 2 shows the mean, mode, SD, and
range of three hUC-MSC-EVs samples used in NTA.
hUC-MSC-EVs decreased lymphocyte count in the
peripheral blood
To study the effect of hUC-MSC-EVs on the circulating
immune cells, the peripheral blood was collected and
subjected to full blood count. Figure 4a depicted the
white blood cell counts of the peripheral blood. The
following graphs show the differential cell counts of (b)
neutrophils, (c) lymphocytes, (d) monocytes, (e) eosino-
phils, and (d) basophils in the peripheral blood. CS ex-
posure for 12 weeks observed a non-significant increase
in white blood cell (WBC) count with no reduction seen
following a 2-week self-healing rest period without ex-
posure to CS (CSSH). Treatment with hUC-MSC-EVs
and hUC-MSC-CM did not reduce WBC counts; how-
ever, a non-significant decrease was seen in response to
hUC-MSCs (Fig. 4a). Notably, CS significantly increased
the percentage of lymphocytes compared to the naive
group with no observed mitigation following 2 weeks of
self-healing (CSSH). A significant decrease in the per-
centage of lymphocytes was seen in response to treat-
ment with whole-cell hUC-MSCs (*p < 0.05), whereas a
slight non-significant decrease in response to hUC-
MSC-EVs and hUC-MSC-CM Fig. 4c.
hUC-MSC-EVs alleviates airway inflammation
The analysis on histological scoring was conducted on
the CS effects on the inflammation in rat airway and
lung parenchyma. Figure 5a showed the histological
image of peribronchial, (b) histological image of the par-
enchyma, (c) semi-quantitative histological scoring and
analysis of airway inflammation, (d) semi-quantitative
histological scoring of lung parenchymal inflammation.
The results showed an increase in inflammation scores
in response to CS (Fig. 5a, b). The accumulation of im-
mune cells significantly increased in the lung paren-
chyma. Meanwhile, 2 weeks of self-healing (CSSH) did
not reduce the inflammation. However, there was a sig-
nificant reduction of inflammation scores observed in
the parenchyma following treatment with hUC-MSC-
EVs, whole-cell hUC-MSCs, and hUC-MSC-CM (**p <
0.001, ***p < 0.0001) (Fig. 5c, d).
hUC-MSC-EVs reduce the infiltration of the immune cells
in the lung
The accumulation of immune cells (neutrophils, eosino-
phils, lymphocytes, and macrophages) in the lung is a
key marker for the development of chronic inflammation
in COPD. Figure 6 showed semi-quantitative histological
scoring and analysis of (a) neutrophils, (b) eosinophils,
(c) lymphocytes, and (d) macrophages in the lung. Our
result showed that CS caused an influx of these immune
cells into the lung (Fig. 5), predominantly neutrophils
and macrophages, while lymphocytes and eosinophils
remained present at low levels. Two weeks of self-
healing (CSSH) failed to reduce the infiltration of all cell
types examined. Notably, the administration of hUC-
MSC-EVs, hUC-MSCs, and hUC-MSC-CM significantly
reduced the immune cell influx as compared to the CS
group.
Table 1 The expression analysis of hUC-MSC surface marker
using flowcytometry









HLA DR DP DQ 0.0
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hUC-MSC-EVs, hUC-MSCs, and hUC-MSC-CM decreased
mucus production
To assess mucus overproduction, the semi-quantitative
histological analysis was conducted to count the inci-
dence of goblet cells between the groups (Fig. 7). Histo-
logical sections of the bronchi were stained with AB-
PAS where the cell nucleus was stained blue, while gob-
let cells stained magenta (Fig. 7a). Statistical analysis
shows that treatment of the CS groups with MSCs had
significantly reduced the number of goblet cells (p <
0.05) as compared to CS and self-healing (CSSH), and
far better than the groups that received treatments with
hUCMSC-EVs and hUCMSC-CM (Fig. 7b).
hUC-MSC-EVs decreased emphysema
To study the effect of CS and treatment intervention on
emphysema, the mean linear intercept of the alveolar
pores were measured on H&E histological slides (Fig. 8a).
Quantitative analysis showed that 12 weeks of CS expos-
ure caused alveolar destruction with a significant in-
crease in the mean linear intercept of the alveolar pores
(Fig. 8b), while 2 weeks of self-healing failed to mitigate
these effects (CSSH). However, a significant (*p < 0.05)
reduction in the mean linear intercept of the alveolar
pores and restoration of tissue was observed following
treatment with hUC-MSC-EVs. Meanwhile, a non-
significant reduction was observed in hUC-MSCs and
hUC-MSC-CM.
hUC-MSC-EVs decreased the levels of p65 in lung tissue
p65 is a subunit of the prototypic, pro-inflammatory
transcription factor NF-κB. Translocation of p65 to the
nucleus of a cell is indicative of the cell pro-
inflammatory response. To study the translocation of
p65 into the nuclei of cells, IHC stained and imaged
lung tissue sections were quantified following CS and
treatment intervention. A significant increase in the per-
centage of p65-positive cells was observed in the CS
group. Following 2 weeks of self-healing, a significant re-
duction of p65 was observed. Treatment with hUC-
MSC-EVs, hUC-MSCs, and hUC-MSC-CM further re-
duced the p65 expression in the CS-exposed lung
(Fig. 9).
CS, hUC-MSC-EVs, and hUC-MSCs alter the gene
expression
Our microarray analysis aimed to determine the path-
ways and the differential gene expressions altered in the
CS-induced lung inflammation and the treatment group
(hUC-MSC-EVs and hUC-MSCs). Differentially expressed
genes (DEG) which has been upregulated or downregu-
lated more than the two fold difference (p < 0.05) are con-
sidered significant for further investigation to understand
the biological, cellular, and molecular functions. CS expos-
ure was shown to lead to a total of 17,689 DEG, while
treatment with hUC-MSC-EVs and hUC-MSCs is shown
to have led to 15,160 and 23,485 DEG, respectively
(Fig. 10a). The heat map shows the different regulation of
DEG from the CS group as compared to the naive, hUC-
MSC-EVs, and hUC-MSCs groups (Fig. 10b). The PCA
plot shows a cluster of samples (n = 2) in the CS, hUC-
MSC-EVs, and hUC-MSCs groups, but high variation was
observed in the naive group (Fig. 10c). The volcano plot
shows DEG in the CS, hUC-MSC-EVs, and hUC-MSCs
groups (Fig. 10d). The Venn diagram shows the overlap-
ping DEG among CS, hUC-MSC-EVs, and hUC-MSCs
(Fig. 10e). A total of 9888 DEG were overlapped in 3
groups, 1610 DEG were overlapped between CS and
Fig. 2 Differentiation of hUC-MSCs. hUC-MSCs differentiate into adipogenesis, osteogenesis, and chondrogenesis, under the differentiation
medium. Adipogenesis was evidenced by the formation of lipid droplet stained red, the formation of osteogenesis was evidenced by calcification
stained red, and the formation of cell-matrix stained blue evidenced chondrogenesis
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hUC-MSC-EVs, 4597 DEG were overlapped between CS
and hUC-MSCs, and 1976 DEG were overlapped between
hUC-MSC-EVs and hUC-MSCs.
Gene Ontology analysis
GO slim analysis of the biological process was per-
formed on the DEG results presented in the tables
below. The enriched GO terms were identified in the CS
(Suppl 1 Table A), hUC-MSCs (Suppl 1 Table B), and
hUC-MSC-EVs (Suppl 1 Table C) groups. The GO
terms for the CS group are related to the regulation of
the cellular process, regulation of catalytic activity, regu-
lation of signalling, and regulation of the metabolic
process, while GO terms for hUC-MSC-EVs are related
to the regulation of catalytic activity, movement of a cell
or subcellular component, regulation of signalling, regu-
lation of cell communication, cellular protein modifica-
tion process, and regulation of RNA metabolic process.
GO terms for hUC-MSCs are related to chemical synap-
tic transmission, sensory perception of the chemical
stimulus, G-protein-coupled receptor signalling pathway,
regulation of signalling, regulation of cell communica-
tion, ion transport, regulation of biological quality, de-
velopmental process, and ribosome biogenesis.
Pathway analysis
The selection of the regulated pathways related to
COPD was determined based on the significant value of
p < 0.05. Thirty-eight pathways were significantly regu-
lated in response to CS, whereas, following hUC-MSC-
EVs treatment, 58 pathways were significantly regulated,
and only 17 pathways were significantly regulated fol-
lowing treatment with hUC-MSCs. The notable path-
ways which were highly regulated in the CS and hUC-
MSC-EVs groups include the TGF-β receptor signalling
pathway, IL-4 signalling pathway, and TNF-alpha NF-kB
signalling pathway. Meanwhile, pathways which were
highly regulated in response to the hUC-MSCs group in-
clude the TNF-alpha NF-kB signalling pathway, senes-
cence and autophagy pathway, and IL-9 pathways. All
the significantly regulated pathways are shown in Suppl
2.
Gene expression
We look for the highest frequency of genes that are reg-
ulated in the pathways in the injury (CS) and treatment
(hUC-MSCs and hUC-MSC-EVs) groups. Table 3 shows
10 genes with the highest frequency in CS. NFKB1 and
Mapk1 are expressed in 11 and 12 pathways, respect-
ively, followed by Jun and Map 2k1, which are regulated
in 10 pathways. Table 4 shows 8 genes with the highest
frequency in the hUC-MSC-EVs group. Akt1 is
expressed in 22 pathways; meanwhile, Mapk1, NFKB1,
and Map 2k1 are regulated in 18 and 15 pathways re-
spectively. Table 5 shows 8 genes with the highest fre-
quency in the UCMSCs group. Akt1 and Mapk1 are
regulated in 6 pathways, while Map 2k1 and TGFB1 are
regulated in 5 and 4 pathways, respectively.
Fig. 3 Characterization of hUC-MSC-EVs. a Morphological observation using EFTEM of hUC-MSC-EVs showed to be rounded in shape. b CD63
expression was observed by western blot analysis. β-Actin is visible at 42 kDa, and CD63 is visible at 30–65 kDa. c Particle distribution by
Nanosight NS300 reported an average hUC-MSC-EVs diameter of 153 nm. Representative data from three independent experiments
Table 2 Analysis of hUC-MSC-EVs size distribution
Sample Mean (nm) Mode (nm) SD (nm) Range (nm)
1 141.2 115.0 51.4 36–737
2 156.5 116.9 68.4 64–795
3 163.0 123.1 68.3 25–740
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Discussion
Our study aimed to determine the effects of hUC-MSC-
EVs in comparison with hUC-MSCs for the treatment of
COPD. The therapeutic potential of MSCs and MSC-
derived secreted factors have been widely demonstrated
in various diseases, including rheumatoid arthritis,
asthma, and Crohn’s disease [33, 64, 77]. In COPD,
MSCs’ capabilities to mitigate inflammation have been
tested in the preclinical and clinical setting around the
world [8, 56, 83]. However, little is known about the ef-
fect of extracellular vesicles isolated from MSCs for the
treatment of inflammation in COPD. hUC-MSCs used
in this study were positive for CD73, CD90, CD105, and
CD166 and negative for CD34, CD45, CD31, and HLA
DR DP DQ as previously described by [85].
Meanwhile, the differentiation analysis showed the
ability of hUC-MSCs to differentiate into adipocyte,
osteocyte, and chondrocyte. hUC-MSC-EVs isolated
from hUC-MSCs showed a rounded morphology with
an average of 153 nm in diameter, and protein analysis
showed a positive marker for CD63 exosomal marker.
Following 12 weeks of CS exposure, the evidence of ac-
cumulation of inflammatory cell infiltrated in peribron-
chial and perivascular tissues as well as the parenchyma,
goblet cell hyperplasia, expression of p65, and the devel-
opment of emphysema, was consistent to that of previ-
ously published studies [62, 94] indicating the
development of COPD by CS inhalation. Two weeks of
self-healing has significantly reduced the expression of
p65 but did not reduce the inflammation and remodel-
ling the destruction of alveolar in the lung. The treat-
ment of hUC-MSC-EVs, hUC-MSCs, and hUC-MSC-
CM significantly reversed the effect of sidestream CS on
lung inflammation, expression of p65, and emphysema.
Our study on microarray also revealed that CS signifi-
cantly regulated the pathways related to COPD and up-
regulated genes related to inflammation including
NFKB1, p65, and protein kinase Cζ (PRKCZ), while
Fig. 4 White blood and differential cell counts of the peripheral blood in the naive and injury groups. a White blood cell counts of the peripheral
blood in the naive and CS groups show an increase in response to CS with no significant decrease following treatments. The following graphs
show the differential cell counts for b neutrophils, c lymphocytes, d monocytes, e eosinophils, and f basophils in the peripheral blood. No
significant increase in neutrophils, monocytes, eosinophils, and basophils was observed in CS. However, the percentage of lymphocytes
significantly increased in response to CS, followed by a decrease following treatment with hUC-MSC-EVs and hUC-MSCs (*p < 0.05)
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treatment with hUC-MSC-EVs and hUC-MSCs were ob-
served to reverse these CS-induced gene expression
effects.
Cigarette smoke is the leading risk factor of COPD,
with over 80% of all COPD cases attributed to cigarette
smoking. Therefore, cigarette smoke is widely employed
by the researchers to develop the in vivo COPD model
over other inducers such as biomass fuel, lipopolysac-
charide, and elastase [2, 10, 31, 39]. For the establish-
ment of COPD model in animals, the cigarette smoke
was exposed to the animals for a 6-month period in
order to exhibit the severe injury in the lung [42, 48].
However, there are studies which employed a 12-week
cigarette smoke exposure demonstrated characteristic of
COPD including inflammation, airway remodelling, fi-
brosis, goblet cell hyperplasia, and emphysema [35, 40].
This method is more feasible for in vivo study as com-
pared to the 6-month period, which is time-consuming.
Our study is in agreement with the previous studies that
showed 12 weeks of cigarette smoke exposure is suffi-
cient to induce characteristics similar to COPD in SD
rats. Importantly, our method of CS exposure for 2
times/day, 7 days/week for 12 weeks exposure, induced
the emphysema in the rat lung, a characteristic of the
chronic model of COPD [51]. It should be noted that
animal models do not fully mimic human condition, re-
gardless of the types of animal used. The duration of
cigarette smoke exposure and the severity of the injury
Fig. 5 Airway and parenchyma inflammation in the injury and treatment groups. Histological image of peribronchial (a). The histological image
of parenchyma (b). Semi-quantitative histological scoring and analysis of airway inflammation (c). Lung parenchymal inflammation (d). The arrow
on a showed accumulation of immune cells in the peribronchial area when exposed to CS for 12 weeks, and self-healing for 2 weeks did not
reduce the inflammation. The arrow on b showed accumulation of immune cells in the parenchyma area, while 2 weeks of self-healing (CSSH
group) did not reduce the inflammation. The scores for inflammation in the airway and alveolar area significantly reduced following treatment
with UCMSC-EVs, hUC-MSCs, and hUC-MSC-CM (****p < 0.0001) compared to the CS group
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are only equivalent to the Global Initiative for Obstruct-
ive Lung Disease (GOLD) stage I or II diseases (Fricker
et al. [28]).
COPD is characterized by airway and parenchymal in-
flammation that leads to mucus overproduction and em-
physema, although these characteristics may not be
present in all patients, as the emphysematous lung only
occurs in 20% of all COPD patients [1, 14]. Nevertheless,
in the animal model, the presence of emphysema is one
of the important characteristics to confirm the develop-
ment of COPD [20]. On the other hand, mucus overpro-
duction is considered challenging to reproduce in the rat
model due to the low number of goblet cells in the
bronchi [14]. Our study using CS exposure for 12 weeks
in SD rats successfully developed characteristic of COPD
as we can observe the increased influx of immune cells
indicating the development of inflammation in the lung,
increased goblet cell count which shows increase mucus
production, and increased mean linear intercept which
shows the development of emphysema.
Airway inflammation begins with the disruption of the
airway and vascular function, allowing infiltration of im-
mune cells in the lung [67, 70]. In the acute phase of CS
exposure that lasts until the second week, increased neu-
trophils were observed. After the second week, macro-
phage begins to increase, and neutrophils start to decrease
but not fully resolve, indicating that chronic inflammation
began to develop [78]. In our study, the increase in neu-
trophil, eosinophil, lymphocyte, and macrophage counts
was observed; however, neutrophils and macrophages are
the predominant immune cells infiltrating the lung. Our
results also showed that immune cell accumulation was
observed more prominently in the alveolar area rather
than the peribronchial and perivascular areas, which des-
troy the alveolar wall leading to the emphysematous lung.
The accumulation of immune cells in the alveolar
walls are prerequisite for the development of emphy-
sema. Neutrophil elastase (NE) was reported to induce
the epithelial apoptosis and emphysema; meanwhile, ex-
cessive MMP-9 released by macrophage can result in
permanent alveolar destruction [6, 41]. Shapiro et al.
[73] demonstrated that crosstalk between these two cells
is crucial in the development of emphysema. The pres-
ence of neutrophils is essential as neutrophils release NE
that is required to recruit more neutrophils and mono-
cytes into the lung. The study was also reported that
Fig. 6 Infiltration of immune cells in rat lung. Semi-quantitative histological scoring and analysis of a neutrophils, b eosinophils, c lymphocytes,
and d macrophages in the lung. CS increased the infiltration of neutrophils, eosinophils, lymphocytes, and macrophages into the lung. Two
weeks of the self-healing period (CSSH) failed to reduce the infiltration of all cells examined. Treatment with hUC-MSC-EVs and hUC-MSC-CM
significantly (*p < 0.05) reduced the infiltration of neutrophils
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mice deficient of NE (NE−/−) had shown significantly
protected from the development of emphysema. Shapiro
and colleagues further proved that the synergistic effects
of neutrophil and macrophage are required to enhance
the potency of both cells. The absence of NE causes the
tissue inhibitors of metalloproteinases (TIMPs) to inhibit
the action of macrophage elastase. Likewise, the absence
of macrophage elastase caused an increase in α-1 anti-
Fig. 7 Goblet cell counts for the assessment of mucus overproduction. Quantitative histological staining (a) and analysis (b) of goblet cells within
the bronchi. A significant increase in goblet cells was observed after 12 weeks of CS exposure with no reduction following 2 weeks of self-healing
(CSSH). Treatment of the CS groups with MSCs significantly reduced the number of goblet cells and no significant reduction in response to
UCMSC-EVs and UCMSC-CM (*p < 0.05, **p < 0.001)
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trypsin, a major inhibitor of NE. Thus, the presence of
both neutrophils and macrophages is an important fac-
tor in the development of emphysema [73].
CS exposure also causes mucus overproduction, al-
though the symptoms may not be present in all COPD
patients [11]. The mechanism by which CS induced the
overproduction of mucus occurs through activation of
TNF-α converting enzyme (TACE) which cleaved pro-
TNF-α to release TNF-α that activates epidermal growth
factor receptor (EGFR) which results in mucin produc-
tion [71]. The accumulation of neutrophils in the lung
during CS exposure may also exacerbate the mucus
Fig. 8 Mean linear intercept of the cigarette smoke-exposed group. Identification of the findings in the figures shown a representative
histological sections stained with H&E staining for each group. b Semi-quantitative analysis of the mean linear intercept of CS-induced
emphysema in rat lung. CS increased the mean linear intercept, and 2 weeks of self-healing failed to alleviate the alveolar obstruction. Meanwhile,
treatment with hUC-MSC-EVs significantly reduced the mean linear intercept. hUC-MSCs and hUC-MSC-CM did not observe a significant
reduction. *p < 0.05
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overproduction as neutrophils are also in part respon-
sible for the impaired mucociliary clearance, increased
goblet cell count, and excessive mucus production. NE
released by neutrophils increased the expression of
MUC5AC by enhancing the mRNA stability via reactive
oxygen species mechanism [5, 25]. Besides, activation of
TNF-α and subsequent activation epidermal growth fac-
tor pathway can also stimulate NE to induce the expres-
sion of MUC5AC [49].
MSCs have been actively investigated as a potential
therapy for COPD. Clinical studies measuring C-reactive
protein in COPD patient revealed the benefit of MSC
administration in mitigating the inflammation [37]. In
the animal model, MSCs alleviate the inflammation by
reducing the alveolar macrophage, while at the same
time promoting the expression of the anti-inflammatory
cytokine, IL-10, in macrophages [35]. MSCs also reduced
the neutrophil infiltration regardless of the route of ad-
ministration [4]. This therapeutic effects of MSCs are
governed by the release of paracrine factors, including
growth factor, cytokine, and EVs rather than cell-to-cell
contact [27]. Recently, research begins to unravel the
therapeutic effects of MSC-derived EVs and better
understand the mechanism behind this ability. Several
studies have shown anti-inflammatory effects of MSC-
derived EVs in mitigating the inflammation similar to
MSCs. Maremanda et al. [59] study the effect of MSC,
MSC-exosomes, and combination of MSC +MSC-exo-
somes in acute CS exposure in mouse model. The group
measured the total cell count and differential cell count
in BAL fluid. The treatment of MSC, MSC-exosomes,
and combination of MSC +MSC-exosomes decreased
the total cell count, macrophages, neutrophils, and CD4+
T cell count. However, the group did not measure the
accumulation of immune cells in the peribronchial and
parenchyma areas [59]. Apart from CS-induced inflam-
mation, MSC-exosomes also have been shown to modu-
late the differentiation, activation, and proliferation of T
cells in vitro [9]. Reduced number of eosinophils, lym-
phocytes, and airway remodelling were observed in the
animal model of asthma when treated with adipose tis-
sue MSC-EVs [18]. In the rat model of hepatic ischemia-
reperfusion injury, hUC-MSC-EVs inhibited the activity
of the neutrophils by attenuation of respiratory burst
Fig. 9 Immunofluorescence staining of CS-exposed lung. Immunofluorescence staining was conducted to study the expression of a p65 (purple)
and DAPI (turquoise) in the lung. b Percentage of p65 expression in all groups. p65 expression was increased when exposed to CS, and smoking
cessation for 2 weeks significantly reduced the expression of p65. The expression of p65 was further reduced when treated with hUC-MSCs, hUC-
MSC-EVs, and hUC-MSC-CM. *p < 0.05, **p < 0.01, ****p < 0.0001
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and oxidative stress, thus reducing the apoptosis of he-
patocytes [90]. Also, MSC-EVs attenuated the pro-
inflammatory cytokines such as IL-17, TNF-α, RANTES,
MIP1α, MCP-1, CXCL1, and HMGB1 while enhancing
the production of IL-10, PGE2, and KGF [79]. In agree-
ment with the previous studies, our study demonstrated
that hUC-MSC-EVs possess anti-inflammatory similar to
its cell counterpart, hUC-MSCs. The treatment with
hUC-MSC-EVs significantly reduced immune cell accu-
mulation in the lung, especially neutrophil accumulation,
reduced emphysema, reduced protein expression of p65,
and downregulated DEG related to COPD.
To date, there are no treatment options available to re-
generate the lung damage in emphysema. However, stem
Fig. 10 Microarray analysis of significantly regulated genes in the CS-exposed lung. a The bar chart represents the total number of DEG,
downregulated and upregulated DEG with p < 0.05 and FC > 2.0, which are considered significantly regulated. b Heat map shows different DEG
regulation in the CS group as compared to the naive, hUC-MSC-EVs, and hUC-MSCs groups. c PCA plot shows a cluster of samples (n = 2) in the
naive, CS, hUC-MSC-EVs, and hUC-MSCs groups. d Volcano plots of differentially expressed genes obtained from the microarray analysis. The red
dots represent upregulated DEG, while blue dots represent downregulated DEG. p value generated using t test. e Venn diagram shows
overlapping DEG among CS, hUC-MSC-EVs, and hUC-MSCs. A total of 9888 DEG were overlapped in 3 groups, 1610 DEG were overlapped
between CS and hUC-MSC-EVs, 4597 DEG were overlapped between CS and hUC-MSCs, and 1976 DEG were overlapped between hUC-MSC-EVs
and hUC-MSCs
Table 3 Genes with the highest frequency in the CS group
Genes p value FC Frequency
Nfkb1 0.0015 6.0905 11
Mapk1 (ERK2) 0.002193779 7.168577 12
Jun 0.041863125 − 3.24888 11
Map 2k1 (MEK1) 0.0097 3.2654 10
Mapk9 0.0026 − 4.401 8
Crebbp (CBP) 0.0089 − 4.07 9
Prkcz 0.0098 3.6678 8
p65 0.0017 6.3732 8
Grb2 0.0235 − 2.237 7
Src 0.0115 − 2.948 7
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cell-based therapy demonstrates a promising regenera-
tive capability to restore the function of the damaged
lung. MSCs and MSC-CM are shown to restore the lung
function by mitigating the apoptosis in the emphysema-
tous lung [42]. This anti-apoptosis effect is in part medi-
ated by vascular endothelial growth factor (VEGF) and
VEGF receptor [36]. Besides, MSCs reduced the expres-
sion of cyclooxygenase-2 in alveolar macrophage,
thereby mitigating the emphysema in a rat model of
COPD [35].
On the other hand, relatively few studies were con-
ducted to decipher the effects of MSC-derived EVs in
the emphysematous lung. The study by Kim et al. [47]
compared the regenerative effects of nanovesicles gener-
ated from adipose stem cells (ASC) and ASC-derived
exosomes in the elastase-induced emphysematous lung.
The result showed that nanovesicles significantly re-
duced the emphysema via its cargo content, FGF2, while
no significant reduction of emphysema was observed in
ASC-derived exosome [47]. In a study examining the ef-
fect of MSC-exosome on bronchopulmonary dysplasia, a
chronic lung disease in the preterm infant, characterized
by restricted lung growth, subdued alveolar and blood
vessel development and impaired pulmonary function;
MSC-exosomes are shown to reduce the mean linear
intercept, while increasing the lung alveolarization,
through alteration of macrophage pro-inflammatory M1
phenotype into anti-inflammatory M2 phenotype [84].
Our result provides the evidence of hUC-MSC-EVs abil-
ity to reduce emphysema in CS-induced COPD in a rat
model. Considering the importance of neutrophil and
macrophage accumulation in the pathogenesis of em-
physematous lung, a significant reduction in the accu-
mulation of neutrophils when treated with hUC-MSC-
EVs and hUC-MSCs in our study in part might explain
the reduction of emphysema. A decrease in macrophage
accumulation was also observed when treated with
hUC-MSC-EVs, hUC-MSCs, and hUC-MSC-CM, al-
though the reduction was not significantly different from
the injury group. Recent studies also reported that MSC-
derived microvesicles reduced the influx of neutrophils
through the effects of KGF [97]. However, macrophages
are shown to play an essential role in MSC anti-
inflammatory effects by changing from M1 to M2
phenotype which produces IL-10 that involve in the re-
duction of inflammation when treated with MSCs and
MSC-EVs [24, 35, 75]. Although the accumulation of
macrophages is prerequisite for emphysema, however, in
allergic asthma, depletion of alveolar macrophage re-
versed the immunosuppressive effect of MSCs in which
the production of IL-10 was dependent on the presence
of alveolar macrophage [60]. The macrophages’ role
might explain why macrophages in our study did not
significantly reduce as it aids in MSC anti-inflammatory
response.
To date, relatively few studies are examining the effect
of MSCs in reducing the mucus overproduction. Al-
though there are reports stating that mucus could be
mitigated with the administration of MSCs, in-depth
analysis of the mechanism involves remaining unknown
[53, 61]. Besides, there is no report on the ability of
MSC-EVs to reduce mucus overproduction. Our study
showed a significant reduction of goblet cell count in
hUC-MSCs. Reduction of goblet cells can be observed in
hUC-MSC-EVs and hUC-MSC-CM; however, the reduc-
tion was not significant. The extracellular environment
can alter the MSCs’ fate and the paracrine factors re-
leased by the MSCs [80]. Thus, the hUC-MSCs trans-
planted into the lung will be influenced by the lung
microenvironment, and the paracrine factors that are be-
ing released by the transplanted MSCs will be different
from the hUC-MSC-EVs and hUC-MSC-CM collected
from the hUC-MSCs grown in the flask, thereby will
affect the lung differently. This effect can be observed in
the various pathways that hUC-MSCs and hUC-MSC-
EVs regulated in our study. We also speculate that hUC-
MSC-EVs and hUC-MSC-CM can affect the lung tissues
faster than hUC-MSCs, as hUC-MSCs will also need to
establish cell-to-cell contact, and the lung
Table 4 Genes with the highest frequency in the hUC-MSC-EVs
group
Gene p value FC Frequency
Akt1 0.00172 − 4.53957 22
Nfkb1 0.003537 − 4.44685 15
Map 2k1 0.003896 − 3.49505 15
Pik3r1 0.002295 5.379887 14
Mapk1 0.010161 − 3.689022 18
Grb2 0.003507 − 3.40208 12
Prkcz 0.006365 − 3.68258 10
p65 0.001438 − 5.04044 10
Table 5 Genes with the highest frequency in the hUC-MSCs
group
Gene p value FC Frequency
Tgfb1 0.024022 − 5.81517 4
Akt1 0.004107 − 6.88884 6
Mapk1 0.001274641 − 8.08983 4
Pik3r1 0.001114 9.6399 4
Map 2k3 0.002436 − 4.57343 4
Mapk3 0.01819 2.465821 4
Mapk8 0.006342 − 3.81553 4
Map 2k1 3.85E-04 − 9.33631 5
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microenvironment will also have to communicate with
hUC-MSCs, in order for hUC-MSCs to produce an ef-
fect. Meanwhile, MSC-EVs and paracrine factors in
MSC-CM can readily be taken up by the cells in the
lung due to its small size [19]. Hence, we observed more
reduction of goblet cell count in the MSC-EVs and
MSC-CM treatment groups as compared to MSCs
alone.
Our microarray analysis aimed to determine the path-
ways associated with COPD and gene expression profile
in our COPD model. We also seek to understand how
the treatment with hUC-MSC-EVs and hUC-MSCs can
change the gene expression profile and pathways in
COPD model. Our DEG analysis of microarray data re-
vealed the importance of p50, p65, and PRKCZ in our
animal model. Twelve weeks of CS exposure significantly
upregulated p50, p65, and PRKCZ, and the treatment
with hUC-MSC-EVs significantly downregulated the ex-
pression of these genes. Immunohistochemistry staining
on p65 confirms the significant upregulation of p65 pro-
tein in the CS group and significant downregulation of
p65 when treated with hUC-MSC-EVs, hUC-MSCs, and
hUC-MSC-CM. Our study was also revealed that p50,
p65, and PRKCZ were involved in many pathway regula-
tions that include the TNF-α NF-κβ signalling pathway,
IL-2 signalling pathway, oxidative stress, oestrogen sig-
nalling pathway, and IL-4 signalling pathway.
The expression of PRKCZ and NF-κβ play a vital role
in inflammation and thus the pathogenesis of COPD.
PRKCZ is upstream of NF-κβ, phosphorylating p65 at
serine 311 to promote the acetylation of Lysine 310, thus
activating the κβ transcription [22]. Mice deficient of
PRKCZ was found to reduce myeloperoxidase and influx
of neutrophils, and reduced pro-inflammatory cytokines
such as IL-13, IL-17, IL-18, IL-1β, TNF-α, MCP-1, MIP-
2, and IFN-γ, while the use of PRKCZ inhibitors blocked
the activation of NF-κβ by TNF-α, thus reducing the
pro-inflammatory IL-8 expression [7, 89]. Meanwhile,
NF-κβ was composed of five members, NF-κβ1 (p50),
NF-κβ2 (p52), RelA (p65), RelB, and c-Rel, that regulate
a multitude of genes involved in inflammatory responses
[55]. Among all heterodimers of NF-κβ, p50/p65 hetero-
dimer represents the most abundant NF-κβ activated by
the canonical pathway [32].
Cigarette smoke activates NF-κβ within 1 h of expos-
ure to the lung thus causing inflammatory reactions
which increase white blood cell count, lymphocyte
count, and granulocyte count [15, 26]. Data from the
pre-clinical study showed 4 weeks of CS exposure signifi-
cantly increased p65 and Iκβα in mouse lung as com-
pared to the control group [92]. NF-κβ is also required
by IL-1β and IL-17A to induce the expression of
MUC5B in bronchial epithelial cells that cause goblet
hyperplasia in COPD [30]. Besides, various studies
demonstrated the upregulation of p65 and p50 expres-
sion in COPD patients [12, 21, 81, 96]. Microarray study
conducted by Yang et al. [87] revealed the vital role of
p50 in regulating many pathways of COPD including
Toll-like receptor signalling pathway, cytokine-cytokine
receptor interactions, chemokine signalling pathway, and
apoptosis [87].
Our study revealed the downregulation of PRKCZ,
p65, and p50 expression when treated with hUC-MSC-
EVs. p50 regulated 18 pathways in the hUC-MSC-EVs
group, while PRKCZ and p65 regulated 10 pathways
suggesting the vital role of the NF-κβ pathway in hUC-
MSC-EVs therapeutic effects in our model. Downregula-
tion NF-κβ subunit by hUC-MSC-EVs can affect mul-
tiple pathways in our model, thus reducing the
inflammation. MSC-EVs have been shown to decrease
the expression of NF-κβ in an in vitro model of cystic fi-
brosis and experimental colitis [88, 98]. MSC-exosomes
also interfered with TLR-4 signalling of BV2-microglia,
which prevented the degradation of NFκβ inhibitor,
Iκβα, and phosphorylation of MAPK family protein in
response to LPS stimulation [82]. However, much is still
unknown about how MSC-EVs regulate the NF-κβ path-
way. In our study, we did not elucidate the cargo content
of hUC-MSC-EVs that is responsible for the anti-
inflammatory effects on CS-induced lung inflammation.
Nevertheless, the study demonstrated that micro-RNA
content of MSC-derived exosome could reduce p50 NF-
κβ pathway in macrophage, thus preventing the Toll-like
receptor-induced macrophage activation [65]. In
addition, CCR2 in MSC-derived exosomes abolished the
ability of CCL2 to induce p65 phosphorylation in macro-
phages [74]. Meanwhile, knockdown of GPX-1 in human
MSCs,reverses the effect of MSC-derived exosomes in
reducing the phosphorylation of p65 [86]. These results
proved that multiple cargo contents of MSC-EVs play a
vital role in mediating the inflammation.
Conclusion
Our study had successfully isolated the hUC-MSC-EVs
from hUC-MSCs. Twelve weeks of CS exposure induced
the inflammation and increased goblet cell count and
emphysema in the rat model. The treatment with hUC-
MSC-EVs, hUC-MSCs, and hUC-MSC-CM decreased
the inflammation in the lung and decreased the goblet
cells, and destruction of the lung in a rat model of
COPD similar to hUC-MSCs. hUC-MSC-EVs reduced
the inflammation in part by the expression of PRKCZ,
and NF-κβ subunits p65 and p50, which regulates many
genes responsible for innate and adaptive immune re-
sponse. Confirmation study using immunofluorescence
on p65 showed a similar result as microarray analysis of
DEG. Taken together, there are still limited data demon-
strating the regenerative and the anti-inflammatory
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effects of MSC-EVs to mitigate the inflammation in
COPD. More studies should be conducted to decipher
the anti-inflammatory effects of MSC-EVs as a whole, as
well as exosomes, and microvesicles as different particle
might exhibit different therapeutic effects. Determin-
ation of cargo content of MSCEVs responsible for the
anti-inflammatory effects and the mechanism of action
of the cargo content of MSC-EVs can provide a clear
with the ways toward the goal of using hUC-MSCs as a
new treatment for COPD.
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